Publications

CAFC Says Generic’s Public Statements Make Induced Infringement Claims Plausible,

Quoted, IPWatchdog

Chad Landmon, Hatch-Waxman & Biologics Chair, discusses the impact of Hikma Pharmaceuticals’ motion to dismiss Amarin Pharma, Inc.’s.